How GSK Reduces Errors and Improves Manufacturing Execution with Digitalization
Speed to market remains a key driver for the digitalization of long-standing paper-based processes in drug manufacturing. Bottlenecks such as manual execution and review—all associated with bloated documentation—prevent companies from aligning with the FDA’s vision for advanced manufacturing to achieve continuous improvement. Manufacturers like GlaxoSmithKline (GSK) are embracing Pharma 4.0 and paperless technologies to help bring quality medicines to patients more quickly.
In this on-demand webinar, Andrew Jenkins, Product Director from GSK, and Craig Resnick, VP of Consulting from ARC, discuss:
- Challenges and benefits of switching from paper-based to digital operations
- Solutions that enable pharma manufacturers to digitalize processes such as batch manufacturing execution
- How digitalization processes across the value chain meet evolving business demands
Watch this on-demand webinar to learn more about the latest technologies that improve usability, reduce risk and ensure compliance.
Related Content
How are you keeping up with growing demand? Digitalize batch execution and records with Aspen Production Execution Manager™ to accelerate time-to-market with accuracy while maintaining regulatory compliance.
Executive Brief:
Optimizing Outcomes Across the Pharma Value Chain Network
Video:
Optimizing Outcomes Across the Pharma Value Chain Network
Interactive Infographic:
4 Steps to Optimize Outcomes Across Your Pharma Value Chain Network